Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.

PURPOSE Five years of adjuvant tamoxifen therapy for estrogen receptor (ER) -positive breast cancer is more effective than 2 years of use. However, information on tamoxifen discontinuation is scanty. We sought to identify predictors of tamoxifen discontinuation among older women with breast cancer. PATIENTS AND METHODS Within six health care delivery systems, we identified women >or= 65 years old diagnosed with stage I to IIB ER-positive or indeterminant breast cancer between 1990 and 1994 who had filled a prescription for adjuvant tamoxifen. We observed them for 5 years after initial tamoxifen prescription. We used automated pharmacy records to validate tamoxifen prescription information abstracted from medical records. The primary end point was tamoxifen discontinuation, operationalized as ever discontinuing tamoxifen during 5 years of follow-up. We used Cox proportional hazards to identify predictors of tamoxifen discontinuation. RESULTS Of 961 women who were prescribed tamoxifen, 49% discontinued tamoxifen before the completion of 5 years. Discontinuers were more likely to be aged 75 to less than 80 years (v < 70 years; hazard ratio [HR] = 1.41; 95% CI, 1.06 to 1.87), be aged >or= 80 years (HR = 2.02; 95% CI, 1.53 to 2.66), have an increase in Charlson Comorbidity Index at 3 years from diagnosis (HR = 1.52; 95% CI, 1.18 to 1.95), have an increase in the number of cardiopulmonary comorbidities at 3 years (HR = 1.75; 95% CI, 1.34 to 2.28), have indeterminant ER status (v ER-positive status; HR = 1.36; 95% CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v mastectomy; HR = 1.62; 95% CI, 1.18 to 2.22). CONCLUSION Attention to nonadherence among older women at risk of discontinuation, particularly those receiving BCS without radiotherapy, might improve breast cancer outcomes for these women.

[1]  Robert J Cersosimo,et al.  Tamoxifen for Prevention of Breast Cancer , 2003 .

[2]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. , 1995, Journal of the National Cancer Institute.

[3]  M. Tinetti,et al.  Potential pitfalls of disease-specific guidelines for patients with multiple conditions. , 2004, The New England journal of medicine.

[4]  D. Miglioretti,et al.  Hormone Therapy Prescribing Patterns in the United States , 2004, Obstetrics and gynecology.

[5]  T. Lash,et al.  Advanced age and adjuvant tamoxifen prescription in early‐stage breast carcinoma patients , 2002, Cancer.

[6]  Aliza K Fink,et al.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Michael J. Goodman,et al.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women , 2000, The Lancet.

[8]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[9]  T. Lash,et al.  Breast cancer treatment of older women in integrated health care settings. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. , 2006, The Journal of urology.

[11]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[12]  E. Winer,et al.  NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[14]  H. S. Lau,et al.  Validation of pharmacy records in drug exposure assessment. , 1997, Journal of clinical epidemiology.

[15]  J. Avorn,et al.  The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. , 1997, American journal of hypertension.

[16]  K. Kahn,et al.  Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Bennett,et al.  Early discontinuation of tamoxifen , 2007, Cancer.

[18]  T. Lash,et al.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Fendrick,et al.  Suboptimal statin adherence and discontinuation in primary and secondary prevention populations , 2004, Journal of General Internal Medicine.

[20]  Matthew F. Muldoon,et al.  Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment , 2004, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[21]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[22]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.

[23]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[24]  Timothy L. Lash,et al.  Adherence to tamoxifen over the five-year course , 2006, Breast Cancer Research and Treatment.

[25]  J. Avorn,et al.  Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. , 1996, American journal of public health.

[26]  Eric C. Schneider,et al.  Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use , 2007, Medical care.

[27]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[29]  Catherine Legrand 1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[30]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[31]  E. Grunfeld,et al.  Adherence beliefs among breast cancer patients taking tamoxifen. , 2005, Patient education and counseling.

[32]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.